Curriculum Vitae

Transmissible Spongiform Encephalopathies Advisory Committee

Name: James Lilliard, Jr., Ph.D., M.B.A.

Position Title: Associate Professor

University of Louisville
Department of Microbiology & Immunology
James Graham Brown Cancer Center
University of Louisville
Baxter II Room 304
580 S. Preston Street
Louisville, KY 40202

Tel: ---------------
Fax: --------------
Cell: --------------
Email: james.lillard@louisville.edu

Education

Executive M.B.A. Healthcare Track, May ----, Emory University - Goizueta Business School
Ph.D. Microbiology & Immunology, December ----, University of Kentucky College of Medicine
B.S. Electrical & Computer Science Engineering, March ----, Ohio State University

Professional Experience

Smith & Lucile Gibson Endowed Chair, University of Louisville, School of Medicine 2006-present
Associate Professor - University of Louisville, School of Medicine, Department of Microbiology & Immunology, James Graham Brown Senior Scientist 2006 - present

Adjunct Professor - Morehouse School of Medicine, Immunology Section, 2006 - present
Associate Professor - Morehouse School of Medicine, Immunology Section, 2004 - 2006;
Assistant Professor - Morehouse School of Medicine, Immunology Section, 1999 - 2003;

Adjunct Professor , University of Alabama at Birmingham, Wallace Tumor Institute, 2000-present;

Technology Transfer Officer - Morehouse School of Medicine, 2004-2006;

Internal (financial) valuation of MSM intellectual property.
Identify and contact licensing partners for out- and in-licensing opportunities.
Evaluate scientific and commercial merit of MSM intellectual property.

Chief Executive Officer, Agency for Disease Diagnosis and Prevention, 2001-2003

Development of clinical diagnosis laboratory services (i.e., Clinical Enterprise Solutions) for developing countries
Manage physician enabling software for disease diagnosis in rural settings
R&D and licensing of mucosal vaccines and rapid nucleic acid- and protein- based diagnosis
Manage national and international funding agencies relationships

Postdoctoral Fellow- University of Alabama at Birmingham, Department of Microbiology, Dr. Jerry R. McGhee, 1996-99; Cellular and Molecular Mechanisms of Mucosal Immunology (inflammation, immunity, tolerance). Clinical & Basic Research Projects included:

Recombinant attenuated pathogenic and commensal bacterial carrier vaccines.
Innate chemoattractants as adaptive immunity & inflammation modulators
DNA based vaccines (TT, Influenza, etc.) for mucosal delivery and/or mucosal immunity - plasmid design of DNA encoded antigen (intracellular or extracellular)
Cost reduction management (decreased annual lab spending by 15%)

Study Sections, Review Panels & Advisory Committes

Academy of Microbiologist, Microbial Triggers of Chronic Human Illness Colloquium (2004)
American Association of Immunologists Council Minority Affairs Committee (2004-2007)
DoD Breast Cancer Research Program, Immunological Sciences Peer Review (2004-present)
DoD Prostate Cancer Research Program, Immunological Sciences Peer Review (2003-present)
FDA Transmissible Spongiform Encephalopathy Advisory Committee (2005-present)
NIH Center for Scientific Review, Immunity & Host Defense Study Section (2004 - present)
NIH CSR, Immunology Special Topics Study Section (2002-2003)
Singapore National Medical Research Council, Cancer Peer Review (2003)
Southeastern Center for Emerging Biological Threats Expert Council (2003-2006)

Journals Reviewed

Advance in Clinical Chemistry (2004-2005)
American Journal of Pathology (2005-present)
British Journal of Cancer (2004-present)
Cancer Letters (2005-present)
Cellular & Molecular Biology (2001)
Cytokine (2004-present)
Infection & Immunity (1997-present); Infection & Immunity Editorial Board (2000-02)
Inflammatory Bowel Disease (2004)
Journal of Immunology (1997-present)
Journal of Interferon & Cytokine Research (2000-present)
Journal of Leukocyte Biology (2004-present)
Mechanisms of Ageing and Development (2002-present)
Neoplasia (2005)
Oncogene (2005-present)
Oncology (2005-present)

Academic Service

MSM Intellectual Property Committee (2002 – present); Committee Chair (2004 – present)
MSM Library Committee Member (2002-2005); MSM Nomination Committee (2000-2002)
MSM Microbiology, Biochemistry & Immunology Special Fund Committee Chair (2001-present)

Postdoctoral Fellows Trained

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mentored Students

Research Support - Active

CXCL13-CXCR5 Interaction and Prostate Cancer Cell Firm Adhesion and Bone Metastasis;
Principal Investigator 15%; DoDIdea Award(9/05 - 8/08); $375,000 direct and $157,500 indirect costs.

Role of CCL25-CCR9 in Prostate Cancer Cell Survival and Metastasis; Investigator 5%; DoD
New Investigator Award (9/05 - 8/08); $225,000 direct and $94,500 indirect costs.

The Grady Center for Health Disparities; MSM Subcontract Principal Investigator 5%,
NIH-NCMHD P60 (10/04 – present); $ 4,678,801 direct and $312,498 indirect costs.

Role of RANTES in Pneumococcal Immunopathogenesis; Principal Investigator 30%,
NIH-NIAID R01 (8/04 – 5/08); $ 832,500 direct and $286,650 indirect costs.

Role of Chemokines in Mucosal Immunity; Principal Investigator 25%,
NIH-NCRR G12 (6/01 - 5/06); $ 525,921 direct and $226,146 indirect costs.

Research Support - Pending

Research Support - Planned

Research Support - Past

Role of Innate Factors in Mucosal Immunity; UNCF-Merck Postdoctoral Fellowship (8/98 - 7/99);
$ -------- direct costs.

Cellular and Molecular Mechanisms for Mucosal Immunity; NIH-R01-RSUM (8/97 - 12/99);
Postdoctoral Fellow 100%, $ 250,000 direct and $110,000 indirect costs.

Role of Chemokines in the Induction of Mucosal Immune Responses, SubprojectPrincipal
Investigator 35%, NIH-NIGMS, (8/00 - 7/02); $325,000 direct and $139,504 indirect costs.

Chemokine Mediators of Cerebral Malaria; Investigator; WHO Collaborative Research Project
(3/01 - 2/04); $------------ direct costs.

Role of Chemokines in Ovarian Cancer, Principal Investigator 5%,NIH-NCI SPORE
Initiative (6/02 – 5/03); $50,000 direct & $21,000 indirect costs.

Chemokine-Mediated Induction and Maintenance of Inflammatory Bowel Disease;
Principal Investigator 10%, ADHF/AGA (8/00 - 7/04); $----------- direct costs.

Role of Chemokines is T Cell - Mediated Colitis; Principal Investigator 10%,
NIH-NIDDK R03 (9/00 - 8/04); $150,000 direct and $64,500 indirect costs.

Role of CXCL13-CXCR5 Interactions in Prostate Cancer Metastasis; Subproject Principal
Investigator 5%, NIH-NCI U56 (4/03 – 5/05); $100,000 direct and $42,000 indirect costs.

Role of Chemokines in Prostate Cancer; Principal Investigator 15%,
DoD New Investigator Award (6/01 - 5/05); $225,000 direct and $96,750 indirect costs.

Cellular and Molecular Mechanisms of I-TAC-Mediated Colitis: Induction and Maintenance;
Principal Investigator 20%, CCFA Senior Research Award (1/04 – 12/05); $-------- direct and $------- indirect costs.

Manuscripts (corresponding authorship is indicated by { *} following the author’s name)

J.D. Fetherston, J.W. Lillard, Jr., and R.D. Perry *. 1995. Analysis of the pesticin receptor from Yersinia pestis: role in iron-deficient growth and possible regulation by its siderophore. J. Bacteriol. 177:1824.
J.W. Lillard, Jr., J.D. Fetherston, L. Pedersen, M.L. Pendrak, R.D. Perry *. 1997. Sequence and genetic analysis of the hemin storage (hms) locus from Yersinia pestis. Gene 193:13.
J.W. Lillard, Jr. and J.R. McGhee *. 1997. Adjuvants or live delivery systems for the characterization of mucosal T helper subset responses. Res. Immunol. 148:520.
J.W. Lillard, Jr., H.L. Weiner, C.C. Whitacre, T. Marth, M.G. Vonherrath, and J. Kapp *. 1997 Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res. Immunol. 148:595.
J.W. Lillard, Jr., S.W. Bearden, J.D. Fetherston, and R.D. Perry *. 1999. The hemin storage (Hms +) phenotype of Yersinia pestis is not essential for virulence of bubonic plague in mammals. Microbiology 145:197.
J.W. Lillard, Jr., S.W. Bearden, J.D. Fetherston, and R.D. Perry *. 1999. Why does the bubonic plague bacterium store iron? Microbiology Today 26:32.
H.A. Jones, J.W. Lillard, Jr., and R.D. Perry *. 1999. HmsT, a protein essential for expression of the hemin storage (Hms +) phenotype of Yersinia pestis. Microbiology 145:2117-2128.
P.N. Boyaka, J.W. Lillard, Jr., and J.R. McGhee *. 1999. Recombinant enterotoxins and cytokines for safe targeting of TH1 or TH2 responses to vaccine antigens. Falk Symposium 104:81.
J.W. Lillard, Jr., P.N. Boyaka, O. Chertov, J.J. Oppenheim, and J.R. McGhee *. 1999. Novel mechanisms for the induction of acquired host immunity by neutrophil peptide defensins. PNASUSA 96:651.
J.W. Lillard, Jr., P.N. Boyaka, J. Hedrick, A. Zlotnik, and J.R. McGhee *. 1999. Lymphotactin acts as an innate mucosal adjuvant. J. Immunol. 162:1959.
P.N. Boyaka, J.W. Lillard, Jr., and J.R. McGhee *. 1999. IL-12 and Innate Molecules for Enhanced Mucosal Immunity. Immunologic Res. 20:207.
Boyaka P.N., J.W. Lillard, Jr., S. Yamamoto and J.R. McGhee *. 1999. Mutant enterotoxins and mucosally administered cytokines for safe targeting of Th1- and Th2-type responses by mucosal adjuvants. in Induction and Modulation of Gastrointestinal Inflammation. Kluwer Academic Publishers (Dordrecht, Boston, London) p. 81-93.
J.W. Lillard, Jr., P.N. Boyaka, D.D. Taub and J.R. McGhee *. 2001. Nasally-administered RANTES potentiates antigen-specific mucosal and systemic immune responses. J. Immunol. 166:162.
J.W. Lillard, Jr. *, P.N. Boyaka, S. Singh, and J.R. McGhee. 2001. Salmonella-mediated mucosal cellular immunity. Cell. Mol. Biol. 47:1115.
B. Sarfo, A. Adjei, R. Gyasi, J.W. Lillard, Jr., and J.K. Stiles * . 2002. Alterations in Immuno-modulator gene expression during murine cerebral malaria. Georgia J. Science 60:48.
J.W. Lillard, Jr. *, P.N. Boyaka, U.P. Singh, D.D. Taub and J.R. McGhee. 2003. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood 101:807.
U.P. Singh, S. Singh, D.D. Taub, and J.W. Lillard, Jr. * 2003. Inhibition of IP-10 abrogates colitis in IL-10 -/- mice. J. Immunol. 171:1401.
U.P. Singh, S. Singh, C.T. Weaver, J.R. McGhee, and J.W. Lillard, Jr. * 2003. IFN- g inducible chemokines enhance adaptive immunity and colitis. J. Interferon Cytokine Res. 23:591.
B. Sarfo, S. Singh, J.W. Lillard, Jr., R. Gyasi, H. Armah, A.A. Adjei, P. Jolly, and J.K. Stiles * . 2004. Cerebral malaria upregulates RANTES, CCR3, and CCR5 expression in the cerebrum and cerebellum. Ann. Trop. Med. Parasitol. 98:297.
V.D. Dixit, E.M. Schaffer, R.S. Pyle, G.D. Collins, J.E. Nagel, S.K. Sakthivel, R. Palaniappan, J.W. Lillard, Jr., and D.D. Taub *. 2004. Ghrelin modulates T cell immune responses and attenuates leptin-induced expression of inflammatory cytokines. J. Clin. Inv. 114:57.
U.P. Singh, S. Singh, D.D. Taub, and J.W. Lillard, Jr. * 2004. Granulocyte chemotactic protein–2 mediates adaptive immunity in part through IL-8R b interactions. J. Leuk. Biol. 76:1240.
S. Singh, U.P. Singh, W.E. Grizzle, and J.W. Lillard, Jr. * 2004. CXCL12-CXCR4 Interactions Modulate Prostate Cancer Cell Migration, Metalloproteinase Expression and Invasion. Lab. Inv. 84:1666.
U.P. Singh, S. Singh, R. Palaniappan, D.D. Taub, and J.W. Lillard, Jr. * 2004. vMIP-II: A Viral Chemokine that Differentially Affects Adaptive Mucosal Immunity Compared to Its Mammalian Counterparts. J. Immunol. 173:5509.
S. Singh, U.P. Singh, W.E. Grizzle, and J.W. Lillard, Jr. * 2004. Expression and functional role of CCR9 in prostate cancer cell migration and invasion . Clin.Cancer Res. 10:8743.
H.L. Bumpers *, M.B. Huang, M.D. Powell, W.E., Grizzle, J.W. Lillard, Jr., J. Okoli, V.C. Bond. 2005. Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer. Cancer Biol. Ther. 4:65.
R. Palaniappan, S. Singh, U.P. Singh, S.K. Hollingshead, D.E. Briles, J.C. Paton, E.W. Ades, and J.W. Lillard, Jr. * 2005. Differential PsaA, PspA, PspC, and Ply mucosal and systemic immunity during pneumococcal carriage. Infect. Immunity 73:1006.
E.L. Barr, S. Ouburg, J.U. Igietseme, S.A. Morre, E. Okwandu, F.O. Eko, G. Ifere, T. Belay, Q. He, D. Lyn, G. Nwankwo, J. Lillard, C.M. Black, and G.A. Ananaba. * 2005. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J. Microbiol. Immunol. Infect. 38:244.
Q. He, T.T. Moore, F.O. Eko, D. Lyn, G.A. Ananaba, A. Martin, S. Singh, J.W. Lillard, Jr., J.K. Stiles, C.M. Black, and J.U. Igietseme. * 2005. Molecular basis for the potency of IL-10-deficient dendritic cells as a highly efficient APC system for activating Th1 responses. J. Immunol. 174:4860.
B.Y. Sarfo, H.B. Armah, I. Irune, A.A. Adjei, C.S Olver, S. Singh, J.W. Lillard, Jr. and J.K. Stiles *. 2005. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malaria J. 4:63.
M.L. Renninger, R. Seymour, J.W. Lillard, J.P. Sundberg, H. HogenEsch. 2005. Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice. Exp. Dermatol. 14: 906.
R. Palaniappan, S. Singh, U.P. Singh, S.K. Sakthivel, S. Hollingshead, E.W. Ades, D.E. Briles, D.D. Taub and J.W. Lillard, Jr. * 2006. CCL5 modulates pneumococcal immunity and carriage. J. Immunol. 176: 2346.

Manuscripts In Revision

Patents

09/213,878: “Lymphotactin as an Adjuvant”. This invention relates to the use of lymphotactin as an adjuvant to boost immune responses.

09/212,600: “Chemokines and Epidermal Growth Factors as Mucosal Adjuvants”. This invention relates to the use of mitogenic and chemokinetic factors such as epidermal growth factors, CC and CXC chemokines as adjuvants to boost immune responses.

10/340,848: “PACE-A Microspheres for Delivery of Antigens”. This invention relates to the use and novel preparation of polycaprolactone- and chitosan- coated epichlorohydrin-crosslinked alginate microspheres as carrier systems for mucosal or systemic delivery of both macro- and small- molecules.

10/392,324; US03/08549: “Tumor Cytotoxicity Induced by Modulators of the CXCR4 Receptor”. This invention relates to the use of HIV-1-, HIV-2-, SIV- or FIV- associated gp120 molecules as therapeutic agents against epithelial carcinomas.

10/712,398; US03/36556: “Anti –chemokine and –associated receptor antibodies and uses for inhibition of cancer growth and metastasis.” This invention relates to antibodies or the use of antibodies directed against chemokines that mediate the growth or migration of cancer cells.

10/712,398; US03/36557: “Anti –chemokine and –associated receptor antibodies and uses for inhibition of inflammation”. This invention relates to antibodies or the use of antibodies directed against chemokines that mediate inflammation.

Provisional: “PCL-XP Nano- and Micro-Particles for Delivery of Protein Therapeutics, Pharmaceutics, or Diagnostic Molecules”. This invention relates to the use of polycaprolactone (PCL)- or PCL-peptide-coated planetary milled particles as mucosal or systemic delivery and targeting vehicles.

Honors, Awards, and Appointments

AAI-FASEB Faculty & Mentee Travel Awards (2003-2006)

CCFA Senior Research Scientist Award (2003)

6 AACR Travel Awards (2003, 2004 (2x), 2005 (2x), 2006 (1X)

DoD New Investigator Award (2001)

ADHF /AGA Research Scholar Award (2000)

UNCF-Merck Fellow (1998-99)

AAAS Risk Assessment Fellowship (declined 1998)

American Association for the Advancement of Science Diplomacy Fellowship Finalist (1998)

NIH Investigator Supplement Grant (1998-2000)

NIH Postdoctoral Training Supplement Grant (1997-2000)

Adhoc reviewer, Nature Biotechnology (1997-present)

NIH Postdoctoral Training Grant (1996-97)

NIH Graduate Supplement Training Grant (1994-95, 1995-96)

Ford Foundation Dissertation Fellowship, Honorable Mention (1995-96)

Ford Foundation Pre-doctoral Fellowship, Honorable Mention (1993-94)

Lymon T. Johnson Award (1992-93, 1993-94, 1994-95,1995-96)

University of Kentucky Graduate School-Medical Center Fellowship (1992-93)

NIH Training Grant (1993-94)

Ace Day Award -for seniors in top 10% of their college (1987)

Kodak Scholar (1985-86, 1986-87, 1987-88)

Minority Engineering Awards - Most Outstanding Senior Scholar (1986-87), Most Outstanding

Freshman Scholar (1984-85), Academic Achievement (1984-85, 1985-86, 1986-87 ,1987-88)

National Honor Societies - Alpha Lambda Delta, Phi Eta Sigma, Alpha Kappa Mu, Tau Beta Pi,

Eta Kappa Nu

Invited Lectures

June, 1999. International Congress of Mucosal Immunology, Amsterdam, The Netherlands.
“Links between Innate and Adaptive Immunity”.

March 2000. Yale University, Department of Epidemiology & Public Health - Division of Epidemiology of Microbial Diseases, New Haven, CT. "Links Between Innate & Adaptive Mucosal Immune Responses".

June 2000. Merck Research Laboratories, Department of Clinical Assay Research & Development, West Point, PA. "Evaluation of Humoral & Cellular Immune Responses to Human Vaccines".

February, 2001. City College New York, Department of Biology, New York, NY.
“Links between innate and adaptive mucosal immune responses”.

April, 2001. Research Centers in Minority Institution Cancer Symposium. Atlanta, GA.
“ Role of chemokines and hormones in hyperplasia and cancer”.

June, 2002. Society for Mucosal Immunology International Conference. Orlando, FL.
“MIP-1 a and MIP-1 b differ as mucosal and systemic adjuvants.”

June, 2002. Pasteur Institute: Recent Advances in Immuno-Intervention. Paris, France.
“Role of chemokines in a mouse model of colitis ”.

December, 2002. Research Centers in Minority Institutions International Symposium. Honolulu, HI. “ Role of chemokines in prostate and ovarian cancer”.

December, 2002. Research Centers in Minority Institutions International Symposium. Honolulu, HI. “MIP-1 a and MIP-1 b differ as mucosal and systemic adjuvants”.

April, 2003. Research Centers in Minority Institutions Annual Conference. San Antonio, TX.
“Inhibition of IP-10 Abrogates Colitis in Murine Crohn’s Disease”.

April, 2003. Research Centers in Minority Institutions Annual Conference. San Antonio, TX.
“Role of RANTES in Pneumococcal Immunopathogenesis”.

April, 2003. Research Centers in Minority Institutions Annual Conference. San Antonio, TX.
“Differential CXCR4 and CCR9 Expression by Prostate Carcinomas”.

May, 2003. Medical University of South Carolina, Department of Pathology & Laboratory Medicine. Charleston, SC. “ Role of Chemokines in Mucosal Immunity, Inflammation, and Cancer”.

May, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“RANTES-Mediates Chlamydial Specific Mucosal Immune Responses”.

May, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“CCR5 and PsaA-Specific Correlates of Clinical Pneumococcal Immunity”.

May, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“Role of RANTES in Pneumococcal Immunopathogenesis”.

May, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“Inhibition of IP-10 Abrogates Colitis in Murine Crohn’s Disease”.

May, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“Differential CXCR4 and CCR9 Expression by Prostate Carcinomas”.

July, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“Expression & functional role of CXCR4 & CCR9 in prostate cancer cell metastasis”.

July, 2003. American Association for ImmunologistsAnnual Meeting. Denver, CO.
“Role of CXCR4 & CCR9 in ovarian cancer cell migration and invasion”.

October, 2003. North Carolina Central University. Durham, NC. “Role of Chemokines in Mucosal Inflammation and Cancer Cell Metastasis”.

December, 2003. University of Georgia in Athens. Athens, GA. “Role of Chemokines in Mucosal Immunity and Inflammation”.

December, 2003. University of Alabama at Birmingham Mucosal Immunology Conference.
Birmingham, AL. “Role of Chemokines in Mucosal Immunity and Inflammation”.

January, 2004. University of Kansas Medical College, Kansas City, Kansas. “Role of Chemokines in Mucosal Immunity and Inflammation”.

January, 2004. University of Texas in San Antonio, San Antonio, TX. “Role of Chemokines in Mucosal Immunity and Inflammation”.

February, 2004. Medical College of Ohio, Toledo, OH. “Role of Chemokines in Mucosal Immunity, Inflammation, and Cancer”.

April, 2004. Louisiana State University Health Sciences Center, New Orleans, LA. “Chemokine-Mediated Mucosal Immunopathogenesis”.

April, 2004. Federation of American Societies for Experimental Biology, Washington, DC.
“CXCL13-Mediated Prostate Cancer Cell Migration and Invasion”.

June, 2004. 31st Annual Meeting and Exposition of the Controlled Release Society, Honolulu, HI.
“Oral Delivery of Diptheria Toxoid by PACE-A™ Microspheres”.

January, 2005. Medical University of South Carolina, Charleston, SC. “Role of Chemokines in Mucosal Immunopathogenesis: Signatures of Microbial & Inflammatory Diseases”.

February, 2005. University of Texas Medical Branch, Galveston, TX. “Role of Chemokines in Mucosal Immunopathogenesis: Signatures of Microbial & Inflammatory Diseases”.

April, 2005. Federation of American Societies for Experimental Biology, San Diego, CA.
“Colitis in IL-10 -/- mice is mediated in part by CXCL10 production by CD4 + T cells, neutrophils, and NK cells as well as CXCR3 + dendritic cells”.

April, 2005. Research Centers in Minority Institutions Annual Conference. Houston, TX.
“PACE-A microspheres as vehicles for oral delivery of diptheria and tetanus vaccines”.

July, 2005. University of Louisville, Louisville, KY. “CXCL10- and CCL5-Mediated Mucosal Immunopathogenesis: Signatures of Microbial or Inflammatory Diseases?”.

August, 2005. University of Louisville, Louisville, KY. “CXCL13 Bone Marrow & CXCR5 Prostate Cancer Cell Expression: Functional Roles in Motility & Invasion”.

November, 2005. Emory University, Atlanta, GA. “Chemokine-Mediated Immunity and Inflammation: Signatures of Microbial & Inflammatory Disease”.

Professional and Honorary Organizations

American Association for the Advancement of Science
American Association for Cancer Research
American Association of Immunologists
American Gastroenterological Association
American Society for Microbiology
Association of University Technology Managers
Control Release Society
Licensing Executives Society
Regulatory Affairs Professionals Society
Society for Mucosal Immunology

Continuing Education

August 1999. "Clinical Research Training Program", NIH & University of Alabama at Birmingham, Birmingham, AL. Topics Covered: Clinical Research, Trials, Biostatistics, Epidemiology, Genetics, Ethics, Regulatory Affairs.

November 1999 & 2000. "RA/QA 101: A Regulatory & Compliance Workshop", Regulatory Affairs Professionals Society, Bethesda, MD. Topics Covered: Premarketing, Post Approval, and Enforcement of the Regulatory Processes. Preclinical, Clinical, and Postmarketing Quality Assurance. Global Perspectives.

June 2000. "CDER & Industry's Role in Minimizing the Pharmaceutical Contribution to Medical Errors"; Solvay Pharmaceuticals, Kennesaw, GA. Topics Covered: Benefit-Risk Assessment for Marketed Drugs/Biologicals, Risk Management, Risk Communication, Postmarketing Surveillance.

July 2000. "Foundations in Regulatory Affairs", Regulatory Affairs Professionals Society Web-Based Learning. Topics Covered: Oversight & Regulatory Affairs Data Management.

August 2000. "Regulations of Biologic Products", Regulatory Affairs Professionals Society Web-Based Learning.

March 2002. “Fundamentals of Intellectual Asset Management 101, 102, 103, & 104”, Licensing Executive Society. Topics Covered: Patent, Copyright, Trademark, & Trade Secret Process and Types, Opportunity Assessment, Valuation, License Agreement & Negotiations, Strategic Planning, and IP Management Process Development.

June 2002. “Intermediate Intellectual Asset Management (IAM) 201, 202, 203, & 204”. Licensing Executive Society. Topics Covered: Legalities, Strategy, Valuation, Negotiations, Ethics, and Licensing of Intellectual Asset Management.

October 2002. “AUTM – Start-Up Business Development Course” Topics Covered: Intellectual Property Management, Strategy, Valuation, Licensing, Finance, Business Plan Development.

November 2002. “NIDDK New Investigator Grant Writing Workshop”.

December 2003. “Managing Expectations Licensing, Technology Valuation, IP, and Start-Ups” Association of University Technology Managers.

November 2003. “Immunogenicity of Testing for Protein-Based Therapeutics”, Institute for International Research.

March 2003. “Access Seed Capital to Develop Technology”. The Southeast SBIR Conference.

February 2003. “Inflammation in Drug Discovery & Development”. Strategic Research Institute.

February 2003. “Discovery, Pre-clinical, Clinical Development & Marketing of Antibody Therapeutics”. Strategic Research Institute.

January 2004. “Therapeutic Protein Delivery & Formulation Workshop”. Drug Delivery Partnerships.

Interests
Mentoring disadvantaged youth and religious history

References
Available Upon Request

Teaching Statement

My Ph.D. dissertation research was centered on understanding the molecular mechanisms of Yersinia pestis pathogenesis. Hence, I am able to lecture on the molecular pathogenesis of most bacterial pathogens at a graduate level. My postdoctoral training at the University of Alabama at Birmingham provided me with a solid foundation in immunology and specifically - mucosal immunobiology. My current research focuses on understanding the cellular and molecular mechanisms of chemokine-mediated disease pathogenesis. Thus, I am most comfortable lecturing on subjects pertaining to T cell immunology and mucosal immunology. I currently use cancer cells to study chemokine signaling cascade and I am able to lecture on narrow topics pertaining to cancer cell motility and invasion. Recently, my research team has developed methods using biopolymers (alginate, chitosan, and polycaprolactone) to produce nanospheres and microspheres that encapsulate therapeutic proteins. Therefore, I can lecture on general approaches to biopolymer synthesis and formulation.

Career Statement

My dissertation studies involved the sequence, genetic and physiological characterization of the hemin storage (hms) system from Yersinia pestis, while under the direction of Dr. Robert Perry at the University of Kentucky. As a Postdoctoral Fellow in the laboratories of Dr. Jerry R. McGhee at the University of Alabama at Birmingham, I studied the hallmarks of mucosal immunology. I expanded on my postdoctoral training, drawing from my graduate studies, to study the roles of chemokines in immunopathogenesis at the Morehouse School of Medicine. Specifically, I use nasal tract or lung tropic strains of Streptococcus pneumoniae to study the cellular mechanisms of RANTES-dependent acute inflammation and immunity in the upper / lower respiratory tract. Similarly, poorly regulated immune responses to Mycobacterium avium subspecies paratuberculosis may induce chronic inflammation in the gastrointestinal tract (i.e., inflammatory bowel disease). My laboratory uses an IL-10 knockout mouse model to study the cellular mechanisms of CXCR3-dependent colitis. Unraveling the precise molecular mechanisms responsible for chemokine-mediated migration and invasion are critical to understand the above mentioned host responses. These “cell signaling events” are perhaps best studied using cancer cell lines. Hence, a developing area of research in my laboratory includes understanding the intracellular signaling events caused by chemokines that result in cancer cell (or leukocyte) migration and tissue invasion.

Due to my expertise in both microbial pathogenesis and mucosal immunology, I collaborate with other investigators with specific interests related to mucosal pathogens (e.g., Bacillus anthracis, influenza virus, etc.) or cancer biology (e.g., prostate cancer, ovarian cancer, etc.). Discoveries stemming from my basic science research have resulted in the development of protein therapeutics (chemokines as vaccine adjuvants and anti-chemokine monoclonal antibodies as anti-inflammatory agents); accordingly, my laboratory has developed novel microsphere formulations to orally deliver these recombinant proteins. My research has resulted in invited lectures, publications and patents; it is my sincere hope that my work will contribute to a better understanding of disease pathogenesis and the development of vaccines as well as inflammation and cancer therapeutics. During my tenure at MSM, I also completed an M.B.A. at Emory University’s Goizueta Business School, with a focus in healthcare and biotechnology. My long-term career goals are to be actively involved in full-time academic research and teaching, while contributing to biotechnology enterprises that may result from my research efforts or those of the institution I serve.